Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 31c, provides guidance

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q4 EPS of $0.32, $0.31 better than the analyst estimate of $0.01. Revenue for the quarter came in at $86.31 million versus the consensus estimate of $80.54 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2025 revenue of $280-295 million, versus the consensus of $269.1 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Northrop Grumman wins two U.S. defense contracts worth $38.7m